eISSN: 1896-9151
ISSN: 1734-1922
Archives of Medical Science
Current issue Archive Manuscripts accepted About the journal Special issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
SCImago Journal & Country Rank

 
6/2020
vol. 16
 
Share:
Share:
more
 
 
Cardiology
Letter to the Editor

Prognostic role of traditional cardiovascular risk factors in patients with idiopathic pulmonary arterial hypertension

Serdar Kalemci
1
,
Aydın Sarıhan
2
,
Arife Zeybek
3
,
Nihat Taşdemir
4

1.
Department of Chest Diseases, Medical Park Gebze Hospital, Kocaeli, Turkey
2.
Manisa State Hospital, Manisa, Turkey
3.
Department of Chest Surgery, School of Medicine, Muğla Sıtkı Koçman University, Muğla, Turkey
4.
Department of Radiology, Medical Park Gebze Hospital, Kocaeli, Turkey
Arch Med Sci 2020; 16 (6): 1459–1460
Online publish date: 2019/12/19
Article file
- Prognostic role.pdf  [0.04 MB]
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
 

We have read with great interest the article recently published by Jonas et al. entitled “Prognostic role of traditional cardiovascular risk factors in patients with idiopathic pulmonary arterial hypertension” [1]. In this study we would like to draw attention to some important points.

The authors have shown a possible relationship between the lifespan and severity of the disease and alterations in glucose metabolism and lipid profiles in patients with idiopathic pulmonary arterial hypertension (IPAH). Selective serotonin reuptake inhibitors (SSRI) are worldwide prescribed anti-depressant drugs and they increase the risk of cardiovascular diseases [2, 3]. A recent report has shown that use of SSRI definitely induces pulmonary artery hypertension [4]. However, in this present study, we did not see any information related to the use of SSRI in patients with IPAH and control subjects. Amphetamines, which increase dopamine concentration by inhibiting dopamine reuptake in neuronal synapses, are widely used for treatment of attention-deficit disorders, obesity and narcolepsy [4, 5]. However, abuse of these drugs is also increasing around the world. It is well documented that amphetamines significantly increase the risk of cardiovascular diseases [6]. The authors have never mentioned the drug use between the groups. We suggest that use of SSRIs and amphetamines should be questioned in patients with IPAH.

Conflict of interest

The authors declare no conflict of interest.

References

1 

Jonas K, Waligóra M, Magoń W, et al. , authors. Prognostic role of traditional cardiovascular risk factors in patients with idiopathic pulmonary arterial hypertension. Arch Med Sci. 2019. 15:p. 1397–1406

2 

Biffi A, Scotti L, Corrao G , authors. Use of antidepressants and the risk of cardiovascular and cerebrovascular disease: a meta-analysis of observational studies. Eur J Clin Pharmacol. 2017. 73:p. 487–97

3 

Visco DB, Manhães-de-Castro R, Chaves WF, et al. , authors. Selective serotonin reuptake inhibitors affect structure, function and metabolism of skeletal muscle: a systematic review. Pharmacol Res. 2018. 136:p. 194–204

4 

Garg L, Akbar G, Agrawal S, et al. , authors. Drug-induced pulmonary arterial hypertension: a review. Heart Fail Rev. 2017. 22:p. 289–97

5 

Zhang M, Lv D, Zhou W, et al. , authors. The levels of triglyceride and total cholesterol in methamphetamine dependence. Medicine. 2017. 96:p. e6631

6 

Paratz ED, Cunningham NJ, MacIsaac AI , authors. The cardiac complications of methamphetamines. Heart Lung Circ. 2016. 25:p. 325–32

Copyright: © 2019 Termedia & Banach. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
 
Quick links
© 2020 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe